Pharma major Dr Reddy’s Laboratories Ltd has launched five new generic drugs in the US market in January 2009. The products launched were Levetiracetam tablets (the generic version of UCB Keppra) with annual sales of $1.1 billion in 2008, Omeprazole capsules (the generic version of AstraZeneca’s Prilosec DR) with annual sales of $168 million, and Lamotragine CD chewable tablets (generic version of GlaxoSmithKline’s Lamictal) which had annual sale of $87 million.

Besdies, Divalproex capsules and delayed release pellets (generic version of Abbott’s Depakote) with annual sales of $126 million and Lamotrigine tablets (generic version of GlaxoSmithKline’s Lamictal) with annual sales of $2.3 billion were also launched. These five products add additional breadth and depth to the company’s product portfolio.

Related Dr. Reddys Laboratories Ltd. Links:

Dr. Reddys Lab Share Price

4489.40 -84.90 (-1.86%) Mar 05, 18:59
1 Year Price Chart
Company Name CMP
Sun Pharma Inds. 610.95
Dr. Reddys Lab 4489.40
Lupin 1031.95
Piramal Enterprises 1924.30
Cadila Healthcare 442.20
View more..
Sensex vs Dr. Reddys Lab
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323